InflaRx shares surge 67.48% premarket on positive Phase 2a data for INF904 in HS and CSU.

InflaRx surged 67.48% in premarket trading following the announcement of positive Phase 2a clinical trial results for its oral C5aR inhibitor INF904 in treating hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The trial demonstrated rapid, clinically meaningful reductions in lesion counts and pain scores for HS patients, with sustained efficacy observed four weeks post-treatment. In CSU, INF904 showed significant reductions in Urticaria Activity Scores, particularly in severe cases, with no serious adverse events reported. The company highlighted INF904’s potential as a “pipeline-in-a-product” with a $1 billion addressable market and plans to initiate Phase 2b trials in HS by 2026. These data, coupled with ongoing collaborations and a scheduled webcast to discuss results, fueled investor optimism about INF904’s development prospects and commercial potential.